Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum α-1,2-mannosidase I (ERManI) is a type II transmembrane glycoside hydrolase enzyme that plays a critical role in the maturation and quality control of N-linked glycoproteins within the secretory pathway of eukaryotic cells. It is primarily responsible for trimming a single α-1,2-linked mannose residue from high-mannose oligosaccharides on nascent glycoproteins. This enzyme acts as a key regulator in protein quality control by generating degradation signals on misfolded glycoproteins, marking them for recognition and subsequent degradation via the ER-associated degradation (ERAD) pathway. While originally thought to reside exclusively in the ER, recent studies suggest a predominant localization in the Golgi complex, contributing to both protein folding quality control and retrograde transport mechanisms. Deficiency or dysfunction can disrupt normal protein homeostasis leading to accumulation of misfolded glycoproteins, potentially implicating it in certain congenital disorders of glycosylation (CDG).
Inhibition of α-1,2-mannose trimming from N-glycans
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmic reticulum α-1,2-mannosidase I (ERManI).